@Article{Minkov2019,
journal="Polish Journal of Pathology",
issn="1233-9687",
volume="70",
number="2",
year="2019",
title="CD11c- and CD123-positive dendritic cells in development of antitumour immunity in non-small cell lung cancer patients",
abstract="Our aim was to analyzed the significance of CD11c and CD123 positive DCs and their relations with some clinical and pathologic parameters of patients with non-small cell lung cancer (NSCLC).  The immunohistochemical expression of CD11c and CD123, was evaluated in 40 patients with NSCLC.  After analysis we found that 35.3% of the patients in the T3-4 tumour stage had a high CD11c infiltration in the tumour stroma, while 100% of the patients in the T1-2 tumour stage had low infiltration (p = 0.03). We also found that 71.4%   of patients in the M1 stage had a high infiltration with CD123 in the tumour stroma, whereas only 15.6% of patients without metastases had high infiltration, analogous data are also found in comparing the distribution of CD123 in the tumour border (p = 0.002 or p = 0.002). Comparing the density of CD123 in the border of lymph node involvement, we found that only 7.14% of patients without metastases had low infiltration with dendritic cells, whereas in patients with metastatic lymph nodes that percentage was 41.7% (p = 0.008).  In conclusion results suggest that CD11c- and CD123-positive DCs play an important role in antitumour immunity and can be predictive factor for tumour development in patients with NSCLC.",
author="Minkov, Plamen
and Gulubova, Maya
and Ivanova, Koni
and Obretenov, Evelin
and Ananiev, Julian",
pages="109--114",
doi="10.5114/pjp.2019.87102",
url="http://dx.doi.org/10.5114/pjp.2019.87102"
}